Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciclesonide + levocetirizine + montelukast
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral, Inhalation, Intranasal
01
Overview
A combination therapy consisting of ciclesonide (a corticosteroid), levocetirizine (an antihistamine), and montelukast (a leukotriene receptor antagonist). This combination targets multiple pathways involved in allergic and inflammatory responses. Ciclesonide reduces inflammation in the airways, levocetirizine blocks histamine receptors to reduce allergy symptoms, and montelukast inhibits leukotriene receptors which play a role in both asthma and allergic rhinitis.
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on ciclesonide + levocetirizine + montelukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciclesonide + levocetirizine + montelukast.